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Familial hypercholesterolaemia (FH) is a common genetic disorder of cholesterol metabolism. 
Mutations in key genes, namely LDLR, PCSK9 and Apo B lead to disturbances in lipid regulation with 
affected individuals exhibiting a lifelong elevation of plasma LDL-C, a marked tendency to premature 
atherosclerosis and early coronary heart disease (CHD) events.1, 2 With an autosomal dominant 
pattern of inheritance, only one copy of an abnormal gene is required to produce hyperlipidaemia 
and CHD risk, commonly known as heterozygous FH.     
Unlike many genetic disorders, FH is eminently treatable, especially following the widespread 
availability of potent lipid lowering agents such as statins.  Indeed, early and sustained therapy to 
lower LDL-C in FH patients can have a profound impact on retarding atherosclerosis development 
and preventing premature CHD.  Despite this preventative benefit, FH still remains poorly recognised 
and under-treated.3  With the recent emergence of more potent therapies and new diagnostic and 
screening strategies, there are growing calls to raise awareness of FH across the world, and step up 
population level efforts to find affected individuals.2, 3   
Risk Modelling & Cost Effectiveness 
Population level screening, diagnostic testing and new treatments come at a cost and require 
substantial investment.  At a time of financial austerity the cost-effectiveness and clinical value of 
any new intervention for identifying or treating FH, needs to be clearly demonstrated.  While well-
established methods and metrics exist for cost-effectiveness analyses, they commonly rely on robust 
modelling and projection of risk, which for FH has remained problematic.4  
That patients with FH are at a risk of premature CAD is of course well known.  For example, early 
studies estimated that men with heterozygous FH will have a 50% risk of developing CHD by the age 
of 60 years and women 30%,5 while a recent Norwegian study showed that the mean age of death in 
FH is 60 by which time 93% had cardiovascular disease.6  However, many such studies reporting on 
risk of CHD for FH have been conducted with highly selected populations, including patients at a 
particular stage in life, without accounting for the lifetime risk from high LDL since birth, or the 
variable extent and timing of past treatment especially statins.  Importantly the impact of competing 
risks from traditional risk factors like obesity, hypertension and diabetes are also not frequently or 
fully accounted for.  
In contrast, for non-FH populations, estimates of CHD risk are available from large prospective 
studies of unselected populations free from, or minimally susceptible to, bias.  Risk equations 
derived from these data then permit accounting for population differences and adjustment for 
differing degrees of competing risk factors.7  Thereafter these equations can be incorporated into 
decision analysis models which systematically consider possible outcomes, to inform cost 
effectiveness analyses.4  Unfortunately, comparable risk equations are not available for FH 
populations due to the relative rarity of the condition. Direct use of non-FH risk equations would 
markedly underestimate risk for this group and render any cost effectiveness estimates unreliable. 
Lifetime Risk for FH Patients 
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In this issue of the journal, Villa and colleagues have sought to address this challenge by first 
identifying the least biased population-based study reporting FH and CHD risk, a Danish study of 69K 
people.8  They then used those estimates to “adjust” existing risk equations for primary 
(Framingham) and secondary prevention (REACH 2012) to better reflect the greater risk of events FH 
patients have in comparison to non-FH patients.9  These equations were then incorporated into a 
decision analysis model using a population modelled on participants from a recent clinical trial of FH 
patients,10 to reflect prevalence and distribution of characteristics and risk factors as well as prior 
treatment rates and included scenarios whereby individuals had established CVD, no CVD or acute 
CVD (ACS, HF and stroke).  
The study comes to the remarkable conclusion that, assuming all assumptions are valid, 10 year risk 
for FH patients is close to 47%, or in other words, almost every other FH patient would experience a 
CV event in the next 10 years, with risk being higher for older subjects and lower for those below 40. 
Even more remarkable is the finding that the predicted lifetime risk was as high as 88% for a first CV 
event, meaning that almost every FH patient will experience at least one CV event in their lifetime.  
Compared to a non-FH patient, an FH patient would thus have almost 4 times higher risk of CV 
events over a lifetime.9  
As with any study such as this, multiple assumptions are needed, some of which may or may not 
impact the validity of the findings.  For example it is assumed that the effect of traditional risk 
factors on CHD risk is independent of FH status, yet we know that diabetes is less prevalent among 
FH patients, while statin therapy itself is associated with diabetes risk and thus interactions may 
conceivably exist.11 The validity and assumptions of the original population study which are used to 
adjust the risk estimates could also be questioned given that only partial data was available to make 
the diagnosis of FH, mostly from lipid levels and family history data while genetic mutation data for 
the same population was only available later and may have impacted findings.12 However, even with 
such issues, and anticipation of future refinements to the approach, this study is still useful in 
providing a sense of the scale of lifetime risk for FH patients and the importance of better diagnosis 
and management of FH. 
Challenges around diagnosis of FH  
The primary challenge for FH remains the identification and diagnosis of cases so they can be offered 
early and aggressive therapy.3  The average worldwide prevalence of heterozygous FH was 
considered to be approximately 1 in 500, based on early studies and Hardy Weinberg estimates 
using homozygous FH prevalence.1  However latest genetic epidemiological analysis and next 
generation sequencing data suggest the prevalence may in fact be closer to 1 in 200-250, more than 
double previous estimates.12-14  The higher prevalence however makes the scale of under diagnosis 
even worse with recent estimates indicating that barring a few notable exceptions, only 1% of cases 
have been diagnosed formally in most European countries based on revised prevalence estimates.15  
Currently FH cases are diagnosed using clinical scoring criteria and/or DNA based analysis, mostly in 
an ad-hoc manner, either after a CHD event, routine health screen or a blood test highlighting an 
abnormally high cholesterol value.  Cascade testing is a systematic approach to finding additional 
cases, by testing the relatives of confirmed FH patients and can be done through genetic mutation 
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analysis or through lipid levels. The approach is recommended by professional societies and has 
been successfully implemented in countries such as the Netherlands.3 However, finding the index 
cases themselves is the limiting factor for cascade testing.  Formal national screening programs are a 
better option in this regard and the feasibility of child screening has been shown in Slovenia where 
all 5 year olds are tested for lipids with genetic testing for those with elevated levels.16  Expanding 
further, Wald et al examined an even more attractive reverse-cascade approach by testing 10,000 
infants 1-2 years of age at the time of vaccination and (using a total cholesterol cut off of the 95th 
percentile) finding in total 40 affected children and at the same time 40 affected parents.17  
However, such approaches are highly dependent on the threshold of LDL levels used for screening. 
Furthermore, genotyping and sequencing in large populations has demonstrated that only ~2% of 
people with elevated lipid levels have a genetic mutation for FH, illustrating the difficulty with only 
using lipid levels to diagnose or screen for FH.13, 14 In addition, 27% of FH mutation carriers have LDL 
levels <3.3mmol/L indicating the incomplete phenotypic penetrance of the genetic mutation, 
although carriage of an FH genetic mutation still elevates CHD risk for any given level of LDL 
compared to non-carriers.13, 14  These definition uncertainties, along with absence of proven long 
term benefit of cascade testing or screening, along with the extensive cost of infrastructure and 
resources needed to implement them, may partly explain the ongoing lack of progress in identifying 
FH in countries around the world.  
Challenges around treating FH 
Since the clinical complications of atherosclerosis occur prematurely, lifelong treatment, started as 
early as possible is needed to reduce the risk of future cardiovascular disease.  Statin therapy in 
patients with heterozygous FH is highly effective and has been shown to lower atherosclerosis 
progression and also cardiovascular events.18  Statin use in children is also safe and effective, with 
guidelines advocating starting therapy at ages 8-10.19   
However, many patients with confirmed or potential FH still do not achieve adequate LDL lowering.3  
A recent study using electronic health record data, estimated that only 58% of those with an FH 
mutation were on statins and only than 46% of these achieved an LDL target of <1.8mmol/L.13  This 
may partly be due to suboptimal dosing, under-appreciation of risk by clinicians, treatment 
resistance or statin intolerance.  Additional drug options include ezetimibe and more recently PCSK9 
inhibition, with the latter able to reduce LDL levels by more than 60%.10  In non-FH patients PCSK9 
inhibition has shown improvements in CV outcomes and atheroma regression, with an expectation 
of similar benefit for those with FH.20  Thus with these and newer agents also emerging, barriers to 
better LDL control for FH patients will no longer be simply due to lack of available therapeutic 
options.   
Ultimately, demonstration of the cost effectiveness and benefit of the diagnostic and screening 
strategies as well as novel therapies for FH will determine whether we will succeed in reducing the 
burden of CHD due to this condition.  The work by Villa and colleagues highlights the high lifetime 
risk of FH patients, and will inform the ongoing scientific and policy discussions. On final related 
note, by using standard CV risk equations, this paper is also a gentle reminder that in our FH 
patients, in addition to treating the LDL, we should not forget to address the many other risk factors 
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we usually treat in non-FH patients, and to maintain a broader perspective on lifetime cardiovascular 
risk.21      
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